Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: A pre-specified secondary study on ectopic fat accumulation
Open accessAbstract
Abstract Aims/hypothesis The aim of this work was to assess the effect of liraglutide on ectopic fat accumulation in individuals with type 2 diabetes mellitus. Methods This study is a pre-specified subanalysis of the MAGNetic resonance Assessment of VICTOza efficacy in the Regression of cardiovascular dysfunction In type 2 diAbetes mellitus (MAGNA VICTORIA) study, with primary endpoints being the effects of liraglutide on left ventricular diastolic and systolic function. The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >25 kg/m2) who were randomly assigned (1:1, stratified for sex and insulin use) to receive liraglutide 1.8 mg once daily or placebo for 26 weeks, added to standard care. Participants, study personnel and outcome assessors were blinded to treatment allocation. The secondary endpoints of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and epicardial fat were measured with MRI. Hepatic triacylglycerol content (HTGC) and myocardial triacylglycerol content (MTGC) were quantified with proton MR spectroscopy. Between-group differences (change from baseline) were tested for significance using ANCOVA. Mean differences with 95% CIs were reported. Results The trial was completed in 2016. Twenty-four participants were randomised to receive liraglutide and 26 to receive placebo. One patient in the liraglutide group withdrew consent before having received the study drug and was not included in the intention-to-treat analysis. Liraglutide (n = 23) vs placebo (n = 26) significantly reduced body weight (liraglutide 98.4 ± 13.8 kg to 94.3 ± 14.9 kg; placebo 94.5 ± 13.1 kg to 93.9 ± 13.2 kg; estimated treatment effect −4.5 [95% CI −6.4, −2.6] kg). HbA1c declined in both groups without a significant treatment effect of liraglutide vs placebo (liraglutide 66.7 ± 11.5 mmol/mol to 55.0 ± 13.2 mmol/mol [8.4 ± 1.1% to 7.3 ± 1.2%]; placebo 64.7 ± 10.2 mmol/mol to 56.9 ± 6.9 mmol/mol [8.2 ± 1.0% to 7.5 ± 0.7%]; estimated treatment effect −2.9 [95% CI −8.1, 2.3] mmol/mol or −0.3 [95% CI −0.8, 0.2]%). VAT did not change significantly between groups (liraglutide 207 ± 87 cm2 to 203 ± 88 cm2; placebo 204 ± 63 cm2 to 200 ± 55 cm2; estimated treatment effect −7 [95% CI −24, 10] cm2), while SAT was reduced by a significantly greater extent with liraglutide than with placebo (liraglutide 361 ± 142 cm2 to 339 ± 131 cm2; placebo 329 ± 107 cm2 to 333 ± 125 cm2; estimated treatment effect −29 [95% CI −51, −8] cm2). Epicardial fat did not change significantly between groups (liraglutide 8.9 ± 4.3 cm2 to 9.1 ± 4.7 cm2; placebo 9.6 ± 4.1 cm2 to 9.6 ± 4.6 cm2; estimated treatment effect 0.2 [95% CI −1.5, 1.8] cm2). Change in HTGC was not different between groups (liraglutide 18.1 ± 11.2% to 12.0 ± 7.7%; placebo 18.4 ± 9.4% to 14.7 ± 10.0%; estimated treatment effect −2.1 [95% CI −5.3, 1.0]%). MTGC was not different after treatment with liraglutide (1.5 ± 0.6% to 1.2 ± 0.6%) vs placebo (1.3 ± 0.5% to 1.2 ± 0.6%), with an estimated treatment effect of −0.1 (95% CI −0.4, 0.2)%. There were no adjudicated serious adverse events. Conclusions/interpretation Compared with placebo, liraglutide-treated participants lost significantly more body weight. Liraglutide primarily reduced subcutaneous fat but not visceral, hepatic, myocardial or epicardial fat. Future larger studies are needed to confirm the results of this secondary endpoint study. Trial registration ClinicalTrials.gov NCT01761318. Funding This study was funded by Novo Nordisk A/S (Bagsvaerd, Denmark).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests.
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [149]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredLiraglutide primarily reduces SAT but fails to decrease visceral, hepatic, myocardial or epicardial fat.
“One recent placebo-controlled trial study reports that liraglutide primarily reduced SAT, but failed to decrease visceral, hepatic, myocardial or epicardial fat [124].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works
Goodman, S. N., & Berlin, J. A. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00008 · Cited by 658 · see citing works
Rijzewijk, L. J., van der Meer, R. W., Smit, J. W. A., Diamant, M., Bax, J. J., Hammer, S., Romijn, J. A., de Roos, A., & Lamb, H. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.062 · Cited by 559 · see citing works
Self-citationMahabadi, A. A., Berg, M. H., Lehmann, N., Kälsch, H., Bauer, M., Kara, K., Dragano, N., Moebus, S., Jöckel, K.-H., Erbel, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.062 · Cited by 529 · see citing works
Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source
Chau, Y.-Y., Bandiera, R., Serrels, A., Martínez-Estrada, O. M., Qing, W., Lee, M., Slight, J., Thornburn, A., Berry, R., McHaffie, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2922 · Cited by 518 · see citing works
Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription
Ishii, S., Iizuka, K., Miller, B. C., & Uyeda, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405238101 · Cited by 416 · see citing works
Kreier, F., Fliers, E., Voshol, P. J., van Eden, C. G., Havekes, L. M., Kalsbeek, A., Heijningen, C. L. V., Sluiter, A. A., Mettenleiter, T. C., Romijn, J. A., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15736 · Cited by 363 · see citing works
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328 · see citing works
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · see citing works
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works
Chaston, T. B., & Dixon, J. B. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803761 · Cited by 300 · see citing works
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · see citing works
Hammer, S., Snel, M., Lamb, H. J., Jazet, I. M., van der Meer, R. W., Pijl, H., Meinders, E. A., Romijn, J. A., Roos, A., & Smit, J. W. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.068 · Cited by 264 · see citing works
Self-citationDutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · see citing works
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260 · see citing works
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259 · see citing works
Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes
Levelt, E., Mahmod, M., Piechnik, S. K., Ariga, R., Francis, J. M., Rodgers, C. T., Clarke, W. T., Sabharwal, N. K., Schneider, J. E., Karamitsos, T. D., et al. (2015) · Diabetes · doi:10.2337/db15-0627 · Cited by 254 · see citing works
Liraglutide causes large and rapid epicardial fat reduction
Iacobellis, G., Mohseni, M., Bianco, S. D., & Banga, P. K. (2017) · Obesity · doi:10.1002/oby.21718 · Cited by 251 · see citing works
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · see citing works
Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes
Levelt, E., Pavlides, M., Banerjee, R., Mahmod, M., Kelly, C., Sellwood, J., Ariga, R., Thomas, S., Francis, J., Rodgers, C., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.597 · Cited by 222 · see citing works
Kreier, F., Kap, Y. S., Mettenleiter, T. C., van Heijningen, C., van der Vliet, J., Kalsbeek, A., Sauerwein, H. P., Fliers, E., Romijn, J. A., & Buijs, R. M. (2006) · Endocrinology · doi:10.1210/en.2005-0667 · Cited by 183 · see citing works
Kooijman, S., Wang, Y., Parlevliet, E. T., Boon, M. R., Edelschaap, D., Snaterse, G., Pijl, H., Romijn, J. A., & Rensen, P. C. N. (2015) · Diabetologia · doi:10.1007/s00125-015-3727-0 · Cited by 140 · see citing works
Self-citationBizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137 · see citing works
Self-citationTang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133 · see citing works
Santilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di Castelnuovo, A., Sborgia, C., Bonadonna, R. C., Angelucci, E., Federico, V., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0589 · Cited by 114 · see citing works
Park, H. S., & Lee, K. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01395.x · Cited by 100 · see citing works
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97 · see citing works
Self-citationWu, L., Wang, K., Wang, W., Zheng, W., Wang, P., Liu, L., & Wang, D. W. (2018) · Aging Cell · doi:10.1111/acel.12763 · Cited by 93 · see citing works
Li, C.-J., Yu, Q., Yu, P., Yu, T.-L., Zhang, Q., Lu, S., & Yu, D.-M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-36 · Cited by 90 · see citing works
Bi, Y., Zhang, B., Xu, W., Yang, H., Feng, W., Li, C., Tong, G., Li, M., Wang, X., Shen, S., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0638-3 · Cited by 71 · see citing works
Jonker, J. T., de Mol, P., de Vries, S. T., Widya, R. L., Hammer, S., van Schinkel, L. D., van der Meer, R. W., Gans, R. O. B., WEBB, A. G., Kan, H. E., et al. (2013) · Radiology · doi:10.1148/radiol.13121631 · Cited by 63 · see citing works
Self-citationSuzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H., Tanaka, E., Kuriyama, Y., Miyatake, H., Abe, M., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8961 · Cited by 61 · see citing works
MR Imaging Evaluation of Cardiovascular Risk in Metabolic Syndrome
van der Meer, R. W., Lamb, H. J., Smit, J. W. A., & Roos, A. (2012) · Radiology · doi:10.1148/radiol.12110772 · Cited by 57 · see citing works
Self-citationGLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction
Pastel, E., McCulloch, L. J., Ward, R., Joshi, S., Gooding, K. M., Shore, A. C., & Kos, K. (2017) · Clinical Science · doi:10.1042/cs20160803 · Cited by 49 · see citing works
Leonardini, A., D’Oria, R., Incalza, M. A., Caccioppoli, C., Buccheri, V. A., Cignarelli, A., Paparella, D., Margari, V., Natalicchio, A., Perrini, S., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00970 · Cited by 36 · see citing works
Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes
van Eyk, H. J., van Schinkel, L. D., Kantae, V., Dronkers, C. E. A., Westenberg, J. J. M., Roos, A., Lamb, H. J., Jukema, J. W., Harms, A. C., Hankemeier, T., et al. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-017-0016-7 · Cited by 36 · see citing works
Self-citationShi, L., Zhu, J., Yang, P., Tang, X., Yu, W., Pan, C., Shen, M., Zhu, D., Cheng, J., & Ye, X. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.01.003 · Cited by 32 · see citing works
Parameter optimization for reproducible cardiac 1H‐MR spectroscopy at 3 Tesla
de Heer, P., Bizino, M. B., Lamb, H. J., & WEBB, A. G. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25254 · Cited by 24 · see citing works
Self-citationMR of Multi-Organ Involvement in the Metabolic Syndrome
Bizino, M. B., Sala, M. L., de Heer, P., van der Tol, P., Smit, J. W. A., WEBB, A. G., Roos, A., & Lamb, H. J. (2014) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2014.09.010 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627 · see citing works
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330 · see citing works
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299 · see citing works
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230 · see citing works
Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00179-0 · Cited by 202 · see citing works
Chew, N., Mehta, A., Goh, R. S. J., Zhang, A. A. Y., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A. C., Dimitriadis, G. K., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 185 · see citing works
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 160 · see citing works
Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137 · see citing works
Self-citationTargher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121 · see citing works
Guo, W., Tian, W., Lin, L., & Xu, X. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108487 · Cited by 126 · see citing works
Silver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15113 · Cited by 94 · see citing works
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87 · see citing works
Pandey, A., Patel, K. V., Segar, M. W., Ayers, C., Linge, J., Leinhard, O. D., Anker, S. D., Butler, J., Verma, S., Joshi, P. H., et al. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13445 · Cited by 80 · see citing works
Weghuber, D., Forslund, A. H., Ahlström, H. K., Alderborn, A., Bergström, K., Brunner, S. M., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., et al. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12624 · Cited by 79 · see citing works
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 82 · see citing works
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74 · see citing works
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63 · see citing works
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 87 · see citing works
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62 · see citing works
Gandoy-Fieiras, N., González‐Juanatey, J. R., & Eiras-Penas, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072641 · Cited by 64 · see citing works
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 61 · see citing works
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 54 · see citing works
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52 · see citing works
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48 · see citing works
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 51 · see citing works
Epicardial adipose tissue in obesity-related cardiac dysfunction
Ayton, S. L., Gulsin, G. S., McCann, G. P., & Moss, A. J. (2021) · Heart · doi:10.1136/heartjnl-2020-318242 · Cited by 49 · see citing works
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44 · see citing works
Bischoff, S. C., Ockenga, J., Eshraghian, A., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Kani, H. T., Khannoussi, W., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.021 · Cited by 45 · see citing works
Epicardial fat and atrial fibrillation: the perils of atrial failure
Poggi, A. L., Gaborit, B., Schindler, T. H., Liberale, L., Montecucco, F., & Carbone, F. (2022) · EP Europace · doi:10.1093/europace/euac015 · Cited by 40 · see citing works
Li, X., Yang, L., & Chen, L. (2024) · International Journal of Endocrinology · doi:10.1155/2024/1785321 · Cited by 39 · see citing works
Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?
Muzurović, E. M., Vujošević, S., & Mikhailidis, D. P. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211006997 · Cited by 41 · see citing works
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Stefan, N., Tilg, H., Byrne, C. D., & Targher, G. (2025) · Liver International · doi:10.1111/liv.70256 · Cited by 48 · see citing works
Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
Berg, G., Barchuk, M., Lobo, M., & Nogueira, J. P. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102562 · Cited by 36 · see citing works
The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
Zhao, N., Wang, X., Wang, Y., Yao, J., Shi, C., Du, J., & Bai, R. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5578216 · Cited by 35 · see citing works
Bao, Y., Hu, Y., Shi, M., & Zhao, Z. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16107 · Cited by 35 · see citing works
Duan, K., Yan, X., Gao, Z., Hou, Y., Lv, X., & Song, G. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13775 · Cited by 33 · see citing works
GLP‐1 analogs and regional adiposity: A systematic review and meta‐analysis
Akoumianakis, I., Zagaliotis, A., Konstantaraki, M., & Filippatos, T. D. (2023) · Obesity Reviews · doi:10.1111/obr.13574 · Cited by 35 · see citing works
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 36 · see citing works
Song, T., Jia, Y., Li, Z., Wang, F., Ren, L., & Chen, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01072-4 · Cited by 33 · see citing works
Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., & Zhang, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0270899 · Cited by 30 · see citing works
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30 · see citing works
Venous thrombosis and obesity: from clinical needs to therapeutic challenges
Rosa, F. L., Montecucco, F., Liberale, L., Sessarego, M., & Carbone, F. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03765-7 · Cited by 29 · see citing works
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28 · see citing works
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eiras-Penas, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 25 · see citing works
Shi, Y., Dong, G., & Guo, M. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.724 · Cited by 24 · see citing works
Dalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 23 · see citing works
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 21 · see citing works
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 26 · see citing works
Shamim, M. A., Patil, A., Amin, U., Roy, T., Tiwari, K., Husain, N., Kumar, J., Chenchula, S., Rao, P. P., Ganesh, V., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15777 · Cited by 23 · see citing works
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 19 · see citing works
Lu, J., Zou, S., Liu, X., Wong, T. Y. P., Zhang, X., Xu, K., Zhao, Y., Hong, Y., Cen, A., & Wang, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177885 · Cited by 19 · see citing works
Dekkers, I. A., Bizino, M. B., Paiman, E. H. M., Smit, J. W. A., Jazet, I. M., de Vries, A. P. J., & Lamb, H. J. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.09.006 · Cited by 19 · see citing works
Self-citationHe, F., Chen, W., Xu, W., Liu, D., Xiao, Z., Tang, Y., Lin, Z., Liao, Y., Bin, J., Chen, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14908 · Cited by 19 · see citing works
Tanaka, K., Fukuda, D., & Sata, M. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0935 · Cited by 18 · see citing works
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 18 · see citing works
Xie, W., Hong, Z., Li, B., Huang, B., Dong, S., Cai, Y., Ruan, L., Xu, Q., Mou, L., & Zhang, Y. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108743 · Cited by 18 · see citing works
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 16 · see citing works
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 21 · see citing works
Yang, Z., Tian, R., Zhang, X., Cai, J., She, Z., & Li, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1120085 · Cited by 16 · see citing works
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 16 · see citing works
Xia, Y., Gao, Z., Yang, C., Duan, K., Ren, L., & Song, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170881 · Cited by 15 · see citing works
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 14 · see citing works
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 14 · see citing works
Lamothe, S., Belalem, I., Vantyghem, M., Nobécourt, E., Mosbah, H., Béliard, S., Delemer, B., Dupuis, H., Vandenbroere, P., Scheyer, N., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16175 · Cited by 14 · see citing works
Wegeberg, A., Meldgaard, T., Bæk, A., Drewes, A. M., Vyberg, M., Jessen, N., Brock, B., & Brock, C. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13575 · Cited by 14 · see citing works
Rasmussen, I. K. B., Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Jensen, J. K., Kjær, A., Hansen, T. W., & Rossing, P. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14516 · Cited by 14 · see citing works
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 13 · see citing works
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15 · see citing works
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 13 · see citing works
Straat, M. E., Martínez‐Téllez, B., van Eyk, H. J., Bizino, M. B., van Veen, S., Vianello, E., Stienstra, R., Ottenhoff, T. H. M., Lamb, H. J., Smit, J. W. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac598 · Cited by 12 · see citing works
Self-citationLiu, L., Xia, Y., Wang, B., & Zhang, Y. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70084 · Cited by 13 · see citing works
Pramanik, S., Pal, P., & Ray, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i2.91319 · Cited by 10 · see citing works
Vincenzi, M., & Nebigil, C. G. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.02.006 · Cited by 10 · see citing works
Zou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 11 · see citing works
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 10 · see citing works
Myocardial steatosis across the spectrum of human health and disease
Oneglia, A. P., Szczepaniak, L. S., Zaha, V. G., & Nelson, M. D. (2023) · Experimental Physiology · doi:10.1113/ep091566 · Cited by 9 · see citing works
Kotha, S., Plein, S., Greenwood, J. P., & Levelt, E. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241229540 · Cited by 9 · see citing works
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 9 · see citing works
Pop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 8 · see citing works
Malik, A., Amjad, W., Inayat, F., Nadeem, M., Weissman, S. I., Malik, M. I., Jajja, A. A., Khan, A., & Tabibian, J. H. (2022) · Gastroenterology Review · doi:10.5114/pg.2022.112775 · Cited by 8 · see citing works
Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29174 · Cited by 8 · see citing works
Self-citationLiraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue
Gu, J., Shao, W., Liu, D., Feng, J. N., Pang, J., & Jin, T. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0026 · Cited by 8 · see citing works
Hara, T., & Sata, M. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2024.1522471 · Cited by 7 · see citing works
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 10 · see citing works
Liu, D., Chen, W., Guo, Z., Gao, Q., Wang, B., Wang, J., Hu, W., Wang, C., Wang, S., Wu, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02763-z · Cited by 7 · see citing works
Wang, X. J., Gong, P., Zhou, C., Huang, C., Lok, U., Tang, S., Taylor, A. L., Eckert, D. J., Chen, S., & Camilleri, M. (2020) · JGH Open · doi:10.1002/jgh3.12464 · Cited by 7 · see citing works
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 7 · see citing works
Xu, Y., Wang, X., She, Y., Liu, J., & Zhang, Q. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0168 · Cited by 6 · see citing works
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Lee, H. A., Lee, H. A., & Kim, H. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79428-6 · Cited by 6 · see citing works
Characterization of the effect of naltrexone/bupropion on body composition
Tardio, V., Yin, P., Camacho, F., Barakat, M., & Tsoukas, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16235 · Cited by 6 · see citing works
Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias
Taqanaki, P. B., Aromolaran, K. A., & Aromolaran, A. S. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70012 · Cited by 6 · see citing works
Benefits of GLP-1 Mimetics on Epicardial Adiposity
Yaribeygi, H., Maleki, M., Nasimi, F. S., Jamialahmadi, T., Stanford, F. C., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230113110431 · Cited by 6 · see citing works
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzı́k, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5 · see citing works
Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity
Li, J., Wu, H., Ma, W., Yuan, T., Chen, X., & Pan, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178133 · Cited by 4 · see citing works
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 4 · see citing works
Qiao, X., Wang, W., Cao, J., Guo, L., & Pan, Q. (2026) · Obesity Reviews · doi:10.1111/obr.70100 · Cited by 4 · see citing works
- Authors
- Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W.
- Affiliations
- Leiden University Medical Center (NL)
- Radboud University Medical Center (NL)
- Corresponding author
- Bizino, Maurice B.
- ORCID
- Venue
- Diabetologia
- Published
- 2019-11-05
- Volume
- 63
- Issue
- 1
- Pages
- 65-74
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6890592
- OpenAlex
- W2985631573
- Cited by
- 123
- References
- 43
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 23 · 2023: 22 · 2022: 18 · 2021: 14 · 2020: 10 · 2019: 1
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Novo Nordisk (NA)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, type 2 diabetes, ectopic fat deposition, visceral adipose tissue, subcutaneous abdominal fat, epicardial adipose tissue, GLP-1 receptor agonists, weight loss, HbA1c, left ventricular function
- MeSH terms
- Liraglutide, Aged, Anthropometry, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Liver, Male, Middle Aged, Myocardium, Triglycerides, Placebo Effect, Subcutaneous Fat, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
